No Data
No Data
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $28
Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (DNLI) and Agilon Health (AGL)
Baird Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $29
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $30
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $30 to $35
Denali Therapeutics Is Maintained at Outperform by Baird